Regardless of mechanism, these data show that fatty-acid synthase (FAS) inhibitors are more toxic at acidic pH, such as that encountered in tumors, and this may be reflected in their strong anti-tumor activity (Kuhajda et al., 2000; Zaytseva et al., 2018). This evidence concerns the gene FASN and neoplasm.